Treatment of male hypogonadotropic hypogonadism and application of recombinant follicle stimulating hormone
10.3760/cma.j.cn101070-20240307-00140
- VernacularTitle:男性低促性腺激素性性腺功能减退症的治疗与重组卵泡刺激素的应用
- Author:
Caihong LIU
1
;
Yan SUN
Author Information
1. 山东第一医科大学附属省立医院东院儿内科，济南 250021
- Keywords:
Hypogonadotropic hypogonadism;
Gonadotropin;
Hypogonadism;
Recombinant follicle stimulating hormone
- From:
Chinese Journal of Applied Clinical Pediatrics
2024;39(11):874-877
- CountryChina
- Language:Chinese
-
Abstract:
Male hypogonadotropic hypogonadism (HH), caused by decreased gonadotropin (Gn), is a group of disorders characterized by lack of pubertal development, cessation or degeneration of secondary sex characteristics, and infertility.Hormone replacement therapy is the primary treatment for this disease and can promote the development of secondary sex characteristics in patients, but the induction of fertility in HH patients with microrchidia is a challenging problem currently.The application of testosterone-based preparations and human chorionic gonadotropin (hCG) alone is not sufficient to improve fertility, while combined treatment of hCG with human menopausal gonadotropin (hMG) injection and gonadotropin-releasing hormone (GnRH) pump can promote testicular sperm production.Recent studies have shown that recombinant follicle stimulating hormone (rFSH) has some positive effects.Especially for patients with severe HH, rFSH pretreatment and sequential treatment are more scientific and effective.This review summarizes the treatment of male HH, focusing on the application of rFSH in this disease, to provide more options for improving male fertility.
